Last reviewed · How we verify
NCT03493841
Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis
Phase 1 trial testing Alpha Lipoic Acid in Multiple Sclerosis in 20 participants. Completed in 25 January 2019.
25 January 2019
Quick facts
| Lead sponsor | Rebecca Spain |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 8 June 2018 |
| Primary completion | 25 January 2019 |
| Estimated completion | 25 January 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Alpha Lipoic Acid
Conditions studied
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
- Progressive Multiple Sclerosis — all drugs for Progressive Multiple Sclerosis →
- Secondary Progressive Multiple Sclerosis — all drugs for Secondary Progressive Multiple Sclerosis →
- Primary Progressive Multiple Sclerosis — all drugs for Primary Progressive Multiple Sclerosis →
Sponsor
Rebecca Spain
Who can join
18 and older, any sex, with Multiple Sclerosis or Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a three-week crossover study that will compare how the body absorbs and tolerates two different forms of lipoic acid: R form and racemic form.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03493841
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Alpha Lipoic Acid
Trials testing the same drug.
- NCT07456176 — Effect of Low-Dose Versus High-Dose Alpha-Lipoic Acid on Oxidative Stress, Inflammation, and Clinical Outcomes in Acute · Phase 3 · not yet recruiting
- NCT07381361 — Photobiomodulation Therapy vs. Alpha-Lipoic Acid in Burning Mouth Syndrome Treatment · NA · active not recruiting
- NCT07256119 — Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients · NA · recruiting
- NCT06195137 — Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.) · NA · completed
- NCT06787781 — Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects · NA · completed
Other recruiting trials for Multiple Sclerosis
Currently open trials in the same condition.
- NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
- NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
- NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
- NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03493841 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rebecca Spain
- Last refreshed: 22 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03493841.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing